Recently, the Ministry of Human Resources and Social Security issued the notice on the inclusion of 36 drugs in category B of the national basic medical insurance, industrial injury insurance and maternity insurance drug list ( hereinafter referred to as the " notice" ), including 36 negotiated drugs in category B of the national basic medical insurance, industrial injury insurance and maternity insurance drug list (2017 edition) ( hereinafter referred to as the drug list ), and simultaneously determined the medical insurance payment standards for these drugs. In April this year, the Ministry of Human Resources and Social Security released a list of 44 drugs to be negotiated. After negotiations with related enterprises, 36 of them were successfully negotiated, with a success rate of 81.8%. Compared with the average retail price in 2016, the average decrease of negotiated drugs reached 44%, with the highest reaching 70%. The payment standard of most imported drugs after negotiation was lower than that of the neighboring international markets, greatly reducing the burden of medical expenses on patients in our country.

Among the 36 drugs included in the drug list this time, 31 western medicines and 5 Chinese patent medicines were included. Fifteen of the western medicines are tumor therapeutic drugs, covering cancer species such as lung cancer, gastric cancer, breast cancer, colorectal cancer, lymphoma, myeloma, etc.. It also includes many tumor targeting drugs being concerned by society and urgently needed by the insured, such as trastuzumab, rituximab, bortezomib, lenalidomide, etc.. The other drugs are for treatment of major diseases or chronic diseases such as cardiovascular disease, kidney disease, eye disease, psychosis, anti-infection and diabetes, as well as recombinant human coagulation factor Ⅶa for hemophilia and recombinant human interferon β-1b for multiple sclerosis. Three of the Chinese patent medicines are tumor medicines and the other two are cardiovascular and cerebrovascular medicines. In addition, the negotiations on access to the medical insurance drug list fully demonstrated the importance and support for medical innovation. All special drugs in the major new drug discovery such as Chidamide, Compaq, Apatini and so on in the scope of the negotiations were successfully negotiated.

This negotiation on the access to the medical insurance drug list was carried out in accordance with the relevant requirements of the notice on printing and distributing the national basic medical insurance, industrial injury insurance and maternity insurance drug list (2017 edition). The negotiation insisted on safeguarding the rights and interests of the insured, equal consultation, combining objective evaluation with expert evaluation, fairness, impartiality and openness, and fully exerted the purchasing function of the basic medical insurance group. While significantly improving the level of medical insurance drug protection, it greatly reduced the social burden, effectively controlled the fund expenditures, basically achieved the goal of " three wins" for the medical insurance, enterprises and the insured, which is conducive to improving the sense of access of the vast number of the insured and guiding reasonable medical behavior and promoting the development and innovation of the medical industry.

Next, the Ministry of Human Resources and Social Security will guide the local authorities to do a good job in the implementation of the negotiated medicines so that the broad masses of the people can truly benefit.

Original link: http://www.mohrss.gov.cn/SYrlzyhshbzb/dongtaixinwen/buneiyaowen/201707/t20170719_274189.html